Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Since the presence of an M-component is an essential disease feature in both multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM), the decrease in the M-protein size applied for response in MM is also a crucial criteria for assessing response in WM. However, WM frequently displays lymphoma-like features that should be included in the response criteria.
Bladé
Joan
J
Department of Hematology, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valentí, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Montoto
Silvia
S
Rosiñol
Laura
L
Montserrat
Emili
E
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D017211:Treatment Failure; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000097:blood* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D007075:Immunoglobulin M